litlas
Log inCreate account

Eric L. Michelson

Active 1978–2019

Also published as
ERIC L. MICHELSON
61
Papers
26,642
Citations
60
h-index
61
i10-index

Citations

Citations per year for Eric L. Michelson1964: 1 citations1972: 1 citations1978: 1 citations1979: 13 citations1980: 31 citations1981: 24 citations1982: 42 citations1983: 48 citations1984: 37 citations1985: 42 citations1986: 18 citations1987: 22 citations1988: 22 citations1989: 26 citations1990: 24 citations1991: 28 citations1992: 13 citations1993: 14 citations1994: 15 citations1995: 14 citations1996: 22 citations1997: 14 citations1998: 11 citations1999: 13 citations2000: 13 citations2001: 12 citations2002: 12 citations2003: 39 citations2004: 128 citations2005: 185 citations2006: 207 citations2007: 215 citations2008: 222 citations2009: 216 citations2010: 218 citations2011: 222 citations2012: 261 citations2013: 224 citations2014: 219 citations2015: 183 citations2016: 167 citations2017: 208 citations2018: 147 citations2019: 550 citations2020: 477 citations2021: 434 citations2022: 322 citations2023: 217 citations2024: 388 citations2025: 163 citations2026: 6 citations1965–1971: no citations, so these years are not shown1973–1977: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,210 citing papers, 23% of this breakdownUnited Kingdom: 840 citing papers, 8.7% of this breakdownItaly: 606 citing papers, 6.3% of this breakdownGermany: 515 citing papers, 5.4% of this breakdownCanada: 505 citing papers, 5.3% of this breakdownNetherlands: 453 citing papers, 4.7% of this breakdownSweden: 344 citing papers, 3.6% of this breakdownFrance: 334 citing papers, 3.5% of this breakdownChina: 289 citing papers, 3% of this breakdownJapan: 275 citing papers, 2.9% of this breakdownAustralia: 259 citing papers, 2.7% of this breakdownSpain: 259 citing papers, 2.7% of this breakdown
0%23%Other 28.2%

Institutions

Fields

  • Medicine93.3%
  • Biochemistry, Genetics and Molecular Biology2.5%
  • Engineering1.1%
  • Health Professions0.5%
  • Nursing0.4%
  • Economics, Econometrics and Finance0.4%
  • Other1.8%

Topics

  • Heart Failure Treatment and Management14.4%
  • Cardiovascular Function and Risk Factors11.1%
  • Cardiac pacing and defibrillation studies4.2%
  • Diabetes Treatment and Management3.8%
  • Cardiac electrophysiology and arrhythmias3.5%
  • Atrial Fibrillation Management and Outcomes3.3%
  • Other59.7%

Coauthors

All papers

Open in search
  1. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

    Authors: Salim Yusuf, Marc A. Pfeffer, Karl Swedberg, Christopher B. Granger, Peter Held, John J.V. McMurray, Eric L. Michelson, Bertil Olofsson, Jan Östergren - The Lancet 2003 cited by 2,984

  2. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

    Authors: Michael R. MacDonald, Mark C. Petrie, Fumi Varyani, Jan Östergren, Eric L. Michelson, James B. Young, Scott D. Solomon, C. B. Granger, Karl Swedberg, Salim Yusuf, Marc A. Pfeffer, John J.V. McMurray, and for the CHARM Investigators - European Heart Journal 2008 cited by 710

  3. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

    Authors: Christopher B. Granger, John J.V. McMurray, Salim Yusuf, Peter Held, Eric L. Michelson, Bertil Olofsson, Jan Östergren, Marc A. Pfeffer, Karl Swedberg - The Lancet 2003 cited by 1,684

  4. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

    Authors: John J.V. McMurray, Jan Östergren, Karl Swedberg, Christopher B. Granger, Peter Held, Eric L. Michelson, Bertil Olofsson, Salim Yusuf, Marc A. Pfeffer - The Lancet 2003 cited by 2,614

  5. Predictors of mortality and morbidity in patients with chronic heart failure

    Authors: Stuart Pocock, Duolao Wang, Marc A. Pfeffer, Salim Yusuf, John J.V. McMurray, Karl Swedberg, Jan Östergren, Eric L. Michelson, Karen S. Pieper, Christopher B. Granger - European Heart Journal 2005 cited by 973

  6. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients

    Authors: Scott D. Solomon, Nagesh S. Anavekar, Hicham Skali, John J.V. McMurray, Karl Swedberg, Salim Yusuf, Christopher B. Granger, Eric L. Michelson, Duolao Wang, Stuart Pocock, Marc A. Pfeffer - Circulation 2005 cited by 880

  7. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure

    Authors: G. Michael Felker, Larry A. Allen, Stuart Pocock, Linda K. Shaw, John J.V. McMurray, Marc A. Pfeffer, Karl Swedberg, Duolao Wang, Salim Yusuf, Eric L. Michelson, Christopher B. Granger - Journal of the American College of Cardiology 2007 cited by 955

  8. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure

    Authors: Hans L. Hillege, Dorothea Nitsch, Marc A. Pfeffer, Karl Swedberg, John J.V. McMurray, Salim Yusuf, Christopher B. Granger, Eric L. Michelson, Jan Östergren, Jan H. Cornel, Dick de Zeeuw, Stuart Pocock, Dirk J. van Veldhuisen - Circulation 2006 cited by 940

  9. Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction

    Authors: Lars Olsson, Karl Swedberg, Anique Ducharme, Christopher B. Granger, Eric L. Michelson, John J.V. McMurray, Margareta Puu, Salim Yusuf, Marc A. Pfeffer - Journal of the American College of Cardiology 2006 cited by 572

  10. Body Mass Index and Prognosis in Patients With Chronic Heart Failure

    Authors: Satish Kenchaiah, Stuart Pocock, Duolao Wang, Peter Finn, Leonardo Antônio Mamede Zornoff, Hicham Skali, Marc A. Pfeffer, Salim Yusuf, Karl Swedberg, Eric L. Michelson, Christopher B. Granger, John J.V. McMurray, Scott D. Solomon - Circulation 2007 cited by 416

  11. Liver Function Abnormalities and Outcome in Patients with Chronic Heart Failure: Data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program

    Authors: Larry A. Allen, G. Michael Felker, Stuart Pocock, John J.V. McMurray, Marc A. Pfeffer, Karl Swedberg, Duolao Wang, Salim Yusuf, Eric L. Michelson, Christopher B. Granger, for the CHARM Investigators - European Journal of Heart Failure 2009 cited by 418

  12. Albuminuria in chronic heart failure: prevalence and prognostic importance

    Authors: Colette E. Jackson, Scott D. Solomon, Hertzel C. Gerstein, Sofia Zetterstrand, Bertil Olofsson, Eric L. Michelson, Christopher B. Granger, Karl Swedberg, Marc A. Pfeffer, Salim Yusuf, John J.V. McMurray - The Lancet 2009 cited by 300

  13. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

    Authors: Marc A. Pfeffer, Karl Swedberg, Christopher B. Granger, Peter Held, John J.V. McMurray, Eric L. Michelson, Bertil Olofsson, Jan Östergren, Salim Yusuf - The Lancet 2003 cited by 1,892

  14. Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure

    Authors: Scott D. Solomon, Joanna Dobson, Stuart Pocock, Hicham Skali, John J.V. McMurray, Christopher B. Granger, Salim Yusuf, Karl Swedberg, James B. Young, Eric L. Michelson, Marc A. Pfeffer - Circulation 2007 cited by 673

  15. Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction

    Authors: James B. Young, Mark E. Dunlap, Marc A. Pfeffer, Jeffrey L. Probstfield, Alain Cohen‐Solal, Rainer Dietz, Christopher B. Granger, J Hradec, J Kuch, Robert S. McKelvie, John J.V. McMurray, Eric L. Michelson, Bertil Olofsson, Jan Östergren, Peter Held, Scott D. Solomon, Salim Yusuf, Karl Swedberg - Circulation 2004 cited by 397

  16. Characterization of Health-Related Quality of Life in Heart Failure Patients with Preserved Versus Low Ejection Fraction in CHARM

    Authors: Eldrin F. Lewis, Gervasio A. Lamas, Eileen O’Meara, Christopher B. Granger, Mark E. Dunlap, Robert S. McKelvie, Jeffrey L. Probstfield, James B. Young, Eric L. Michelson, Katarina Halling, Jonas Carlsson, Bertil Olofsson, John J.V. McMurray, Salim Yusuf, Karl Swedberg, Marc A. Pfeffer, for the CHARM Investigators - European Journal of Heart Failure 2006 cited by 247

  17. Analysing Recurrent Hospitalizations in Heart Failure: A Review of Statistical Methodology, with Application to CHARM-Preserved

    Authors: Jennifer K. Rogers, Stuart Pocock, John J.V. McMurray, Christopher B. Granger, Eric L. Michelson, Jan Östergren, Marc A. Pfeffer, Scott D. Solomon, Karl Swedberg, Salim Yusuf - European Journal of Heart Failure 2013 cited by 221

  18. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

    Authors: Cono Ariti, John G.F. Cleland, Stuart Pocock, Marc A. Pfeffer, Karl Swedberg, Christopher B. Granger, John J.V. McMurray, Eric L. Michelson, Jan Östergren, Salim Yusuf - American Heart Journal 2011 cited by 189

  19. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial

    Authors: Bradi B. Granger, Karl Swedberg, Inger Ekman, Christopher B. Granger, Bertil Olofsson, John J.V. McMurray, Salim Yusuf, Eric L. Michelson, Marc A. Pfeffer - The Lancet 2005 cited by 483

  20. Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure

    Authors: Eileen O’Meara, Tim Clayton, Margaret McEntegart, John J.V. McMurray, Ileana L. Piña, Christopher B. Granger, Jan Östergren, Eric L. Michelson, Scott D. Solomon, Stuart Pocock, Salim Yusuf, Karl Swedberg, Marc A. Pfeffer - Circulation 2007 cited by 279

  21. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

    Authors: Anique Ducharme, Karl Swedberg, Marc A. Pfeffer, Alain Cohen‐Solal, Christopher B. Granger, Aldo P. Maggioni, Eric L. Michelson, John J.V. McMurray, Lars Olsson, Jean L. Rouleau, James B. Young, Bertil Olofsson, Margareta Puu, Salim Yusuf - American Heart Journal 2006 cited by 355

  22. Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker

    Authors: Stevo Julius, Shawna D. Nesbitt, Brent M. Egan, Michael A. Weber, Eric L. Michelson, Niko Kaciroti, Henry R. Black, Richard H. Grimm, Franz H. Messerli, Suzanne Oparil, M. Anthony Schork - New England Journal of Medicine 2006 cited by 922

  23. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme

    Authors: SJ Pocock, John J.V. McMurray, Joanna Dobson, Salim Yusuf, C. B. Granger, Eric L. Michelson, Jan Östergren, Marc A. Pfeffer, Scott D. Solomon, Stefan D. Anker, Karl Swedberg, on behalf of the CHARM Investigators - European Heart Journal 2008 cited by 194

  24. Incidence and Predictors of Hyperkalemia in Patients With Heart Failure

    Authors: Akshay S. Desai, Karl Swedberg, John J.V. McMurray, Christopher B. Granger, Salim Yusuf, James B. Young, Mark E. Dunlap, Scott D. Solomon, James W. Hainer, Bertil Olofsson, Eric L. Michelson, Marc A. Pfeffer - Journal of the American College of Cardiology 2007 cited by 170